Review of ongoing clinical trials in non-small cell lung cancer: A status report for 2009 from the clinicalTrials.gov Website

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1116-1119

  Subramanian, Janakiraman ^a   Madadi, Anusha R ^b   Dandona, Monica ^a   Williams, Kristina ^a   Morgensztern, Daniel ^a,c   Govindan, Ramaswamy ^a,c  

^a WASHINGTON UNIVERSITY   (United States)

^b St Lukes Hospital   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHARMACOLOGICAL BIOMARKER; PROTEASOME INHIBITOR; VASCULOTROPIN INHIBITOR;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL RESEARCH; CONTROLLED STUDY; DRUG INDUSTRY; HUMAN; INTERVENTION STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; UNITED STATES;

EID: 77955094991     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e76159     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Seruga B, Hertz PC, Le LW, et al. Global drug development in cancer: a cross-sectional study of clinical trial registries. Ann Oncol 2009;21:895-900.
3. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-216.
4. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006;25:420-428.
5. Chen TT, Chute JP, Feigal E, et al. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 2000;92:1601-1607.
6. Freidlin B, Breathnach OS, Johnson BE. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2003;9:917-922.
7. Chan JK, Ueda SM, Sugiyama VE, et al. Analysis of phase II studies on targeted agents and subsequent phase III trials: what are the predictors for success? J Clin Oncol 2008;26:1511-1518.
8. Goffin JR, Tu D. Phase II stopping rules that employ response rates and early progression. J Clin Oncol 2008;26:3715-3720.
9. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002;58:823-831.
10. Schiller JH. Clinical trial design issues in the era of targeted therapies. Clin Cancer Res 2004;10:4281S-4282S.
11. Wieand S, Schroeder G, O'Fallon JR. Stopping when the experimental regimen does not appear to help. Stat Med 1994;13:1453-1458.
12. Zia MI, Siu LL, Pond GR, et al. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical che- motherapeutic regimens. J Clin Oncol 2005;23:6982-6991.
13. Herndon JE II. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin Trials 1998;19:440-450.
14. Parmar MKB, Barthel FM-S, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008;100:1204-1214.
15. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer 2006;52:207-212.
16. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
17. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)